Latest profit margin for CanSino Biologics: 2.38% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for 688185.SS is 2.38% as of September 2026. That compares with -14.62% in the prior-year period — up 116.3% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside CanSino Biologics's historical trend and sector peers before judging valuation or financial health.
Over the past year, 688185.SS's profit margin moved from -14.62% to 2.38% — a 116.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CanSino Biologics's valuation or profitability profile.
Against Healthcare companies, 688185.SS currently prints 2.38% for profit margin, while the sector average sits near 17.63%. That is roughly 86.5% below the sector mean. Large gaps often invite a closer look at CanSino Biologics's growth, margins, and balance sheet.
Profit Margin shows how effectively CanSino Biologics converts resources into returns. At 2.38%, 688185.SS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -14.62% in the prior-year period — up 116.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 688185.SS's profit margin (2.38%), review year-over-year change from -14.62%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.